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Abstract: Taxanes are highly active chemotherapeutic agents in the treatment of early-stage and metastatic breast cancer. Novel 
­ formulations­have­been­developed­to­improve­efficacy­and­decrease­toxicity­associated­with­these­cytotoxic­agents.­nab-paclitaxel is a 
solvent free, albumin-bound 130-nanometer particle formulation of paclitaxel (Abraxane®,­Abraxis­Bioscience),­which­was­developed­





phase II   studies have suggested a role for nab-paclitaxel­as­a­single­agent­and­in­combination­with­other­agents­for­first-line­treatment­
of metastatic breast cancer.
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Introduction
Taxanes (eg, paclitaxel, docetaxel) and anthracyclines 
(eg, doxorubicin, epirubicin) remain among the most 
active­and­widely­used­chemotherapy­agents­in­breast­
cancer,­ both­ in­ adjuvant­ and­ metastatic­ settings.1–3 




rating  combination  of  taxanes  and  anthracyclines.4 
However,­ approximately­ 25%–30%­ of­ early­ stage­
breast­cancers­will­recur.­There­is­an­imperative­need­
for agents that not only overcome resistance but also 
have­a­favorable­toxicity­profile.­The­solvents­used­
for dissolving hydrophobic molecules, paclitaxel and 
docetaxel­are­known­to­be­associated­with­significant­
risk­of­hypersensitivity­reactions­and­neuropathy­and­
also impair drug delivery to the tumor, limiting their 
clinical effectiveness.5,6
With the advent of nanotechnology, a novel for-
mulation  of  solvent  free  130-nanometer  albumin-
bound paclitaxel (nab-paclitaxel, Abraxane®, Abraxis 
Bioscience)­ was­ developed­ for­ use­ as­ a­ colloidal­
suspension  intravenously.  Based  on  the  pivotal 







prior therapy included an anthracycline.
This­article­provides­a­review­of­pharmacology,­
safety­ and­ efficacy­ profile­ of­ nab-paclitaxel,  and 
evaluates­its­benefit­in­treatment­of­breast­cancer.
Side-Effects and Drawbacks  
of Solvent-Based Taxanes
Taxanes bind to the interior surface of β-microtubule 
chain and enhance tubulin polymerization, thereby sta-







use. It is a naturally occurring diterpinoid   product 
extracted­from­bark­of­pacific­yew.­Docetaxel,­another­
taxane,­ which­ was­ approved­ by­ FDA­ for­ clinical­
use­in­2004,­is­a­semi-synthetic­esterified­product­
of 10-deacetyl baccatin III extracted from needles 
of­European­yew.­Both­paclitaxel­and­docetaxel­are­
highly­hydrophobic.­Cremaphor­EL­(CrEL),­a­non-
ionic surfactant poly-oxy-ethylated castor oil mixed 
1:1­with­dehydrated­ethanol­was­recognized­to­be­the­
most feasible option to solubilize paclitaxel for intra-
venous­administration.­Likewise,­the­solvent­used­for­
Docetaxel­is­another­poly-oxy-ethylated­surfactant,­
polysorbate-80.6 Being biologically and pharmaco-
logically­active,­these­solvents­are­associated­with­
several­major­side­effects­such­as­hypersensitivity­
reactions and neuropathies. They also impair tumor 
penetration,  limiting  the  clinical  effectiveness  of 
solvent-based  taxanes.5,6­ CrEL-paclitaxel­ formula-
tion needs special infusion set to minimize exposure 
to­ di(2-ethylhexyl)phthalate­ (DHEP),­ which­ may­
be  leached  from  standard  polyvinyl  chloride  sets. 
­ Prolonged­infusion­times­and­premedications­with­
corticosteroids and antihistamine agents are required 
to­reduce­hypersensitivity­reactions.­­ However,­minor­
reactions­ still­ occur­ in­ about­ 40%­ of­ all­ patients­
receiving­ solvent-based­ taxanes­ and­ nearly­ 3%­
develop potentially life-threatening   reactions.6­CrEL­
is­also­shown­to­cause­neutropenia­and­prolonged­
peripheral  neuropathy  related  to  axonal  degenera-
tion.­Fluid­retention,­a­toxicity­commonly­seen­with­
docetaxel has been attributed in part due to alteration 
of­membrane­fluidity­by­polysorbate-80.6,8­­ Formation­
of­ large­ polar­ micelles­ of­ CrEL-paclitaxel­ in­ the­
plasma  compartment  can  cause  entrapment  of  the 
drug­leading­to­non-linear­pharmacokinetics.5 This 
alters the   pharmaco-dymanic characteristics of the 
solubilized drug resulting in a substantial increase 
in­ systemic­ exposure­ with­ concomitantly­ reduced­
systemic­clearance­placing­patients­at­risk­for­severe­




standard-of-care­dose­(175­mg/m2 over 3 hours every 
3­weeks)­have­been­unsuccessful.9­More­frequent­dos-
ing­(such­as­weekly­administration)­which­may­lead­
to increased duration of exposure, has demonstrated 
improved­efficacy­in­both­adjuvant/­ neoadjuvant­and­
metastatic settings.10nab-paclitaxel in breast cancer: safety and efficacy
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To address these limitations of solvent-based tax-
anes and to improve their therapeutic index, various 
solvent-free formulations and delivery systems such 
as liposomal encapsulated paclitaxel, paclitaxel vita-
min­E­emulsion­and­polymer­microsphere­formula-
tion­of­paclitaxel­were­investigated­but­with­limited­
success.6,8­ First­ successful­ attempt­ to­ formulate­ a­
solvent-free  taxane  has  been  the  development  of 
nab-paclitaxel.  The  nano-particle  protein  platform 
utilizes the natural properties of albumin to increase 
drug delivery to the tumor and eliminates the need for 
solvents.
Nanomedicine and nab-Technology
Nanomedicine is the medical application of molecular 
nab-technology,­a­new­area­of­science­that­involves­
working­with­small­scale­materials­and­devices­that­
are at the nanometer level (10-9­of­a­meter).­A­few­
examples of the development by this discipline include 
liposomes, dendrimers, super paramagnetic nanopar-
ticles and polymer-based platforms.11 Albumin has a 
number­of­features­that­make­it­an­ideal­drug­delivery­
system. It is a natural carrier of endogenous hydropho-
bic molecules such as vitamins, hormones and other 
water-insoluble­plasma­substances­that­are­bound­in­
a reversible non-covalent manner. Albumin plays an 
important role in endothelial transcytosis of protein-




of  membrane  vesicles,  resulting  in  receptor  medi-
ated internalization of the albumin-drug complex into 
caveolae (small invaginations of plasma membrane). 
Subsequently,­caveolae­transports­the­albumin-drug­
conjugate­ to­ the­ extracellular­ space,­ including­ the­
tumor­interstitium.­SPARC­(secreted protein, acidic 
and rich in cysteine),­which­is­believed­to­be­selec-
tively secreted by the tumors, binds to albumin-drug 
complex­with­the­resultant­release­of­the­drug­in­the­
vicinity of tumor cells.11,12
Preclinical and Clinical Evaluation  
of nab-Paclitaxel
Comparative intratumoral and antitumoral activity of 
nab-paclitaxel has been demonstrated to be greater 
than­CrEL-paclitaxel­and­docetaxel­in­­ multiple­tumor­
types using preclinical models.12,13­Desai­et­al13 using 
radiolabeled­ paclitaxel­ in­ mice­ with­ xenografts,­
showed­ that­ nab-paclitaxel­ was­ significantly­ less­
toxic;­LD50­(lethal­dose,­50%)­values­and­maximum­
tolerated­dose­(MTD)­for­nab-paclitaxel­and­CrEL-
paclitaxel­ were­ 47­ and­ 30­ mg/kg/day,­ and­ 30­ and­
13.4­mg/kg/day,­respectively.­At­equal­doses,­intratu-
moral­paclitaxel­accumulation­was­found­to­be­33%­
higher for nab-paclitaxel. In live human umbilical vas-
cular­endothelial­cells­(HUVEC),­endothelial­binding­
and transport across the endothelial cell monolayer 
was­significantly­higher­(9.9­fold­and­4.2­fold­respec-
tively)­with­nab-paclitaxel­and­this­difference­was­
abrogated by methyl β-cyclodextrin,­a­known­inhibi-
tor­of­endothelial­gp60­receptor­and­­ caveolar-mediated­
transport.13 Zhou et al recently reported similar anti-
tumoral­responses­with­­ nab-paclitaxel in hepatocel-
luar carcinoma (HCC) cell lines.14 In a panel of HCC 
cell lines studied, nab-paclitaxel­showed­an­effective­
IC50­ dose­ at­ 15-fold­ lower­ than­ paclitaxel­ or­ doc-
etaxel alone, and ∼450-fold­less­compared­to­doxo-
rubicin.­SPARC,­a­type­of­caveolin-1­has­a­sequence­
homology­with­gp60,­leads­to­its­binding­to­albumin.­
It is over expressed in several tumor types includ-
ing­breast­cancer.­This­interaction­between­SPARC­
and albumin has been suggested to be the reason for 
enhanced­uptake­and­intra-tumoral­accumulation,­and­
also­a­possible­role­for­SPARC­as­a­bio-marker­for­
nab-paclitaxel  effectiveness.12  These  data  provided 
the preclinical evidence to advance the drug to clini-
cal studies.
Phase 1 and Pharmacokinetic Studies
Three  different  dose  schedules  of  nab-paclitaxel 
have­been­evaluated­in­Phase­I­and­pharmacokinetics­
  studies. In a study by Ibrahim et al,15­19­patients­with­










was­determined­to­be­300­mg/m2, substantially higher 
than­ the­ typical­ dose­ used­ with­ CrEL-paclitaxel.­
Pharmacokinetic­ analyses­ revealed­ whole­ blood­vishnu and Roy
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In  another  phase  1  trial  reported  by  Nyman 
et al,16­39­patients­with­advanced­non-hematological­
malignancies  received  nab-paclitaxel­ without­ pre-
medication­at­a­dose­levels­from­80­to­200­mg/m2 
as­a­30-minute­infusion­once­a­week­for­3­weeks­
in  each  monthly  cycle.  One  third  of  patients 
received  $6­ cycles.­ After­ enrollment­ of­ the­ first­
cohort,­patients­were­enrolled­into­1­of­2­cohorts,­
‘lightly’ and ‘heavily’ pretreated based on the extent 
of­prior­exposure­to­­ chemotherapy.­MTDs­for­these­
two­cohorts­were­150­mg/m2­and­100­mg/m2; dose-
limiting­ toxicities­ were­ grade­ 3­ peripheral­ neu-
ropathy and grade 4 neutropenia respectively. The 
pharmacokinetics­was­again­noted­to­be­linear­and­
there­ were­ no­ dose-dependant­ changes­ in­ plasma­
­ clearance.­ Partial­ response­ (PR)­ was­ observed­ in­
patients­previously­treated­with­CrEL-paclitaxel.




were­ likely­ to­ be­ responsive­ to­ taxanes­ were­ ran-
domized to receive nab-paclitaxel­(260­mg/m2 as a 
30-minute­infusion)­or­CrEL-paclitaxel­(175­mg/m2 
as a 3 hour infusion). Patients crossed over to the 
alternate treatment after 1st cycle. Thereafter, patients 
received­treatments­with­260­mg/m2 of nab-paclitaxel 
every­3­weeks.­Pharmacokinetic­studies­were­carried­
out­for­the­first­cycle­of­CrEL-paclitaxel­and­the­first­
two­cycles­of­nab-paclitaxel. The total drug expo-
sure­was­comparable­between­the­two­formulations­
and­ the­ mean­ fraction­ of­ unbound­ paclitaxel­ was­
significantly­higher­with­nab-paclitaxel compared to 
CrEL-paclitaxel­(0.063­±­0.021­vs.­0.024­±­0.009;­
P , 0.001). This study purports that systemic expo-
sure­to­unbound­paclitaxel­would­lead­to­increased­
tumoral­ uptake­ thereby­ resulting­ in­ an­ augmented­
anti-tumor­efficacy­compared­to­CrEL-paclitaxel.
In a phase 1 study of three different schedules of 




doses­ranging­from­220­to­340­mg/m2 on day 1 every 
21­days;­group­B­received­nab-paclitaxel at 100 or 
125­mg/m2­on­days­1,­8,­and­15­every­28­days;­and­





icity in all the groups.









65%­ of­ evaluable­ patients­ had­ a­ partial­ or­ stable 
response on this therapy.
Phase II Studies
Based on the results of phase 1 study,15 Ibrahim et al 
investigated nab-paclitaxel in a multicenter phase II 
study to evaluate safety and antitumor   activity in patients 
with­MBC.20­63­women­with­confirmed­and­measur-





















cycle.­ Response­ rates­ were­ 14%­ and­ 16%­ for­ the­
100­mg/m2­and­125­mg/m2­cohorts,­respectively­with­nab-paclitaxel in breast cancer: safety and efficacy
Breast Cancer: Basic and Clinical Research 2011:5  57
an­additional­12%­and­21%­of­patients,­respectively,­
having stable­disease­(SD)­for­$16­weeks.­Median­
progression-free­ survival­ (PFS)­ (3­ vs.­ 3.5­ months)­
and­median­survival­(9.2­vs.­9.1­months)­were­simi-
lar­for­the­two­dose­cohorts;­Survival­was­similar­for­


















(64%),­ fatigue­ (58%),­ sensory­ neuropathy­ (54%),­
infection­ (46%),­ nausea­ (38%),­ alopecia­ (33%),­
and­anemia­(33%).­The­investigators­concluded­that­
Table 1. nab-PACLiTAXeL: AT A GLANCe37
nab-PACLITAXEL: AT A GLANCE37
Mechanism of action
Antimicrotubule agent, promote microtubules assembly from tubulin dimers and stabilize microtubules to prevent 
depolymerization. This stability causes inhibition of the normal dynamic reorganization of the microtubules which is 
necessary for important interphase and mitotic functions in the cells
Dosing and administration
260 mg/m2
intravenous infusion over 30 minutes once every 3 weeks
Pharmacokinetics
Distribution: extensive extra-vascular distribution and/or tissue binding; does not penetrate blood brain barrier
Protein binding: 89% to 98%
Metabolism: Hepatic; P450 (CYP2C8 and CYP3A4)
excretion: Fecal (20%); renal (4%)
elimination half life: 27 hours
Side effects
Common:
Cardiovascular: abnormal eKG (60%), edema (10%)
Dermatologic: alopecia (90%)
Gastrointestinal: diarrhea (27%), nausea (30%), vomiting (18%)
Hematologic: Anemia (33%), Neutropenia, (any grade, 80%)
Hepatic: raised transaminases (39%), raised alkaline phosphatase (36%)
Neurologic: asthenia/myalgia/fatigue (47%), sensory neuropathy (any grade, 71%)
Ophthalmic: visual disturbance (13%)
Renal: raised serum creatinine (11%)
Respiratory: dyspnea (12%)
Serious:
Cardiovascular: cardiac arrest, cerebrovascular accident, supraventricular tachycardia, transient ischemic attack (3%)
Hematologic: severe anemia (1%), bleeding (2%), febrile neutropenia (2%), neutropenia, grade 4 (9%),  
severe thrombocytopenia (,1% )
Neurologic: severe sensory neuropathy (10%)
Special precaution
Paclitaxel has been shown to be clastogenic, teratogenic and fetotoxic and should not be used in pregnancy. Men should 
be advised not to father a child while receiving treatment. it is not known if paclitaxel is excreted in human milk; however, 
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MBC­were­treated­with­125­mg/m2 of nab-paclitaxel 
and­1000­mg/m2 of gemcitabine­on­days­1­and­8­of­
a­21­day­cycle­until­disease­progression.­40­patients­
(80%)­ had­ visceral­ involvement­ and­ 30­ patients­
(60%)­had­$3­sites­of­metastases.­ORR­was­50%­






Gradishar­ et­ al24  reported  a  randomized  multi-
center phase II study comparing nab-paclitaxel­with­
docetaxel­ as­ first­ line­ treatment­ in­ patients­ with­
MBC.­300­previously­untreated­MBC­patients­were­
randomized  to  3  different  nab-paclitaxel  treatment 
­ schedules—300­ mg/m2­ every­ 3­ weeks­ (n­ =­ 76),­
150­mg/m2­weekly­(n­=­74)­and­100­mg/m2­weekly­
(n =­76).­Docetaxel­dose­was­100­mg/m2 once every 
3­weeks­(n­=­74).­43%­of­patients­had­received­prior­
adjuvant­ or­ neoadjuvant­ chemotherapy.­ 150­ mg/m2 
weekly­ nab-paclitaxel­ demonstrated­ significantly­










penia­were­less­frequent­in­all­nab-paclitaxel arms and 
the­frequency­and­grade­of­peripheral­neuropathy­was­






dense nab-paclitaxel for   early-stage breast cancer.25 
Women­ with­ high­ risk­ breast­ ­ cancer­ (T1-3,­ N1-2,­
or­N0­disease­with­tumors­that­were­.2­cm)­were­




adverse­ events­ (AEs),­ including­ myelosuppression.­




959­mg/m2); one discontinued nab-paclitaxel­after­2­
doses due to unacceptable­AEs.­4­patients­had­a­grade­
3 nab-paclitaxel related neuropathy (no grade 4 event). 
Of­29­patients,­34%­received­­ peg-filgrastim­during­
nab-paclitaxel­therapy­and­31%­had­a­  nab-paclitaxel 
treatment delay, mainly due to hematologic toxicity. 
Based­ on­ Kaplan–Meier­ probability­ estimates,­ the­








nab-paclitaxel­ administered­ sequentially­ with­
anthracycline­has­also­been­evaluated­in­a­neoadjuvant­






(FEC)­ every­ 3­ weeks­ for­ 4­ cycles.­ ­ Trastuzumab­
was­ allowed­ in­ HER2-positive­ (HER2+)  patients. 
­ Sixty-three­patients­completed­4­cycles­of­albumin-
bound­ paclitaxel­ following­ which­ 58­ completed­
4­ cycles­ FEC.­ 17­ of­ 19­ HER2+  patients  received 







These  studies  suggest  that  nab-paclitaxel  alone 
or­in­combination­with­other­therapeutic­agents­has­nab-paclitaxel in breast cancer: safety and efficacy
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Table 2. Summary table of Phase ii Clinical trial results.
Study n ORR Median PFS (months) Median survival Ref
Phase II studies assessing the activity of nab-paclitaxel in metastatic breast cancer
ibrahim et al 63 48% (all patients) 
64% (first line treatment)
6.2* 14.6 months 20
Blum et al 181 14% (100 mg/m2) 
16% (125 mg/m2)
3 (100 mg/m2) 
3.5 (125 mg/m2)
9.2 months 21
Roy et al** 50 50% 7.9 NR 23
Gradishar et al 300 45% (100 mg/m2/q week) 
49% (150 mg/m2/q week) 
37% (300 mg/m2/q 3 weeks)
12.8 (100 mg/m2/q week) 
12.9 (150 mg/m2/q week) 
11 (300 mg/m2/q 3 weeks)
NR 24
Notes: *Time to progression; **in combination with gemcitabine.
Abbreviations: ORR, overall response rate; PFS, progression-free survival; NR, not reached.
a­significant­activity­in­patients­with­breast­­ cancer,­





cytotoxic or targeted agents in breast cancer and other 
solid tumors (Table 3).
Phase III Studies
Based on the favorable phase I and phase II data, 
  nab-paclitaxel’s­ antitumor­ efficacy­ and­ safety­
was­ compared­ to­ CrEL-­ paclitaxel­ in­ a­ pivotal,­
  multi-national randomized phase III trial conducted 
at­70­sites­in­5­countries.27­Of­the­460­women­with­
MBC­enrolled­in­the­study,­454­were­randomized­to­
3-weekly­ cycles­ of­ either­ nab-paclitaxel  at  a  dose 
of­260­mg/m2­intravenously­over­30­minutes­with-
out premeditation (n =­229)­or­CrEL-paclitaxel­at­a­
dose­of­175­mg/m2­intravenously­over­3­hours­with­









57.02­ mg/m2/week).­ nab-paclitaxel  demonstrated 
significantly­ higher­ response­ rates­ compared­ with­





nab-paclitaxel­ for­ all­ patients­ (23­ vs.­ 16.9­ weeks;­
hazard­ratio­[HR]­=­0.75;­P =­0.006)­and­among­those­
receiving­ second­ line­ therapy­ or­ greater­ (20.9­ vs.­
16.1­weeks;­HR­= 0.73; P =­0.02).­There­was­no­sig-
nificant­difference­in­median­OS­among­all­patients­
between­ the­ nab-paclitaxel­ and­ ­ CrEL-paclitaxel­
groups­(65­vs.­55.7­weeks;­P =­0.374);­however­in­the­
patients­who­received­nab-paclitaxel as second-line or 
greater­therapy­had­a­significantly­longer­OS­(56.4­vs.­
46.7­weeks;­HR­= 0.73; P =­0.024).­The­incidence­of­
grade­4­neutropenia­was­lower­in­nab-paclitaxel group 







rapidly­ to­ grade­ 1–2­ in­ a­ median­ of­ 22­ days.­ No­
severe­hypersensitivity­reactions­occurred­with­nab-





randomized to receive either nab-paclitaxel­260­mg/
m2­over­30­min­every­3­weeks­with­no­premedica-
tion­ or­ CrEL-paclitaxel­ 175­ mg/m2  over  3  hours 
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icantly higher in the nab-paclitaxel group. The most 
common­ toxicities­ reported­ were­ alopecia­ (78%),­
peripheral­neuropathy­(75%,­7%­grade­3)­and­neutro-
penia­(65%)­and­were­similar­between­the­2­groups.
These trials corroborate the results of the preclin-
ical­and­phase­I/II­clinical­trials­that­the­use­of­the­
nab-paclitaxel formulation could result in clinically 
relevant­improvements­in­the­toxicity­and­the­effi-
cacy of paclitaxel. In particular the incidence of any 
grade­3­and­4­neutropenia­was­significantly­reduced­
in patients receiving nab-paclitaxel­compared­with­
those  receiving  paclitaxel,  despite  an  increase  in 
the­dose­of­paclitaxel.­Grade­3­sensory­neuropathy­
was­higher­with­nab-paclitaxel­but­manageable­with­
quick­ improvement­ to­ lower­ grades.­ Interestingly,­




Therapeutic applicability of nab-paclitaxel­is­now­
being tested in variety of tumor types, including non 
small cell lung cancer, pancreatic cancer and mela-




are listed in Table 4.
Tolerability and Economic Analysis  
of nab-paclitaxel
The overall tolerability of nab-paclitaxel­260­mg/m2 
was­reported­to­be­similar­to­that­of­CrEL-paclitaxel­
175­mg/m2 in the phase III trial.27 No differences in 
quality­of­life­throughout­the­study­were­noted­between­
the­two­treatment­groups­despite­higher­dose-intensity­
of paclitaxel in the nab-paclitaxel­group­(85.13­vs.­
57.02­ mg/m2/week).­The­ most­ commonly­ reported­





vs.­ 21%),­ infections­ (24%­ vs.­ 20%),­ and­ diarrhea­
(26%­vs.­15%)­for­­ nab-paclitaxel­vs.­CrEL-paclitaxel­
groups­respectively.­Fewer­events­of­neutropenia­and­
skin­ flushing­ were­ reported­ among­ nab-paclitaxel vishnu and Roy
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recipients­than­CrEL-paclitaxel­recipients,­where­as­
sensory  neuropathy  and  gastrointestinal  symptoms 
were­ higher­ with­ nab-paclitaxel  but  this  resolved 
more­rapidly­after­treatment­withdrawal.­There­was­
no report of grade 4 sensory neuropathy. The side 
effects are summarized in Table­5.
Dose­ adjustment­ is­ recommended­ in­ patients­
with­ hepatic­ dysfunction,­ neutropenia­ and­ sensory­















neutropenia (neutrophil counts ,­500­cells/mm3 for 
a­week­or­longer)­or­severe­sensory­neuropathy­dur-
ing­treatment­with­nab-paclitaxel should have dos-
age­ reduced­ to­ 220­ mg/m2  for  subsequent  courses 
of   nab-paclitaxel.­For­recurrence­of­severe­neutro-
penia or severe sensory neuropathy, additional dose 
reduction­should­be­made­to­180­mg/m2. Treatment 
should­be­withheld­until­neutrophils­are­greater­than­
1500­cells/mm3 and platelets recover to a level greater 
than­100,000­cells/mm3.­For­grade­3­sensory­neu-
ropathy, treatment is held until resolution to grade 1 
or­2,­followed­by­a­dose­reduction­for­all­subsequent­
courses of nab-paclitaxel. Premedication to prevent 
hypersensitivity  reactions  is  not  required  prior  to 
administration  of  nab-paclitaxel.  The  use  of  nab-
paclitaxel­has­not­been­studied­in­patients­with­renal­
dysfunction. In randomized controlled trials, patients 
were­excluded­for­serum­creatinine­.­2­mg/dL.




product.­Dranitsaris­et­al30 has recently published an 




tured from the trial’s database and an economic anal-
ysis­was­performed­from­the­perspective­of­United­
Kingdom­National­Health­Service­(UK­NHS).­The­
costs  of  chemotherapy,  drug  delivery,  monitoring, 
supportive  care  drugs  and  hospitalization  due  to 
toxicity­was­included.­A­univariate­and­multivariate­
regression­ analysis­ was­ performed­ to­ compare­ the­
total cost of therapy in patients randomized to each 
of the four arms of the study. When all cost compo-
nents­were­combined­for­the­entire­study­population­
(n = 300), patients in nab-paclitaxel­100­mg/m2 once 
Table 5. Adverse events: nab-paclitaxel vs. CreL-paclitaxel.
nab-paclitaxel 
260 mg/m2 




(% patients;  
n = 225)
Adverse events: nab-paclitaxel vs. CrEL-paclitaxel27
Alopecia 90 94
Sensory neuropathy*
  Any grade 71 56
  Severe 10 2
Asthenia
  Any grade 47 38
  Severe 8 3
Neutropenia*
  Any grade 80 82
  Severe 9 22
Febrile neutropenia 2 1
Arthralgia/Myalgia
  Any grade 44 49
  Severe 8 4
Liver enzymes  
elevation
  AST† 39 32








  Any grade 30 21
  Grade $ 3 3 ,1
infections 24 20
vomiting
  Any grade 18 9
  Severe 4 1
Diarrhea*
  Any grade 26 15




Notes: *P , 0.05; †aspartate transaminase.nab-paclitaxel in breast cancer: safety and efficacy












types including breast cancer and may be associated 
with­a­poor­prognosis.­In­preclinical­breast­­ cancer­
models12 and recently in a retrospective   analysis of 
a clinical study31 of nab-paclitaxel­in­head­and­neck­
cancer,­SPARC­expression­and­its­­ interaction­with­
albumin  has  been  suggested  to  be  the  reason  for 
enhanced­uptake­and­intratumoral­accumulation­indi-
cating­a­possible­role­for­SPARC­as­a­bio-marker­for­








nab-paclitaxel in lung cancer
Besides breast cancer, nab-paclitaxel is being investi-
gated­in­a­variety­of­other­solid­tumors.­Results­from­






In another phase II study33­in­elderly­patients­with­





















nab-paclitaxel as a radiosensitizer
Preclinical studies in mice bearing syngeneic ovar-
ian­or­breast­cancer­have­shown­that­nab-paclitaxel 
improved  radiotherapy  in  a  supra-additive  manner 
suggesting that combining nab-paclitaxel­with­radio-
therapy­would­improve­the­outcome­of­taxane-based­
chemoradiotherapy.35
Other nab-compounds in pipeline
The nab technology has potential for improving drug 
delivery­and­enhancing­therapeutic­ratio­of­other­water-
insoluble­drugs.­Three­such­drugs­with­­ nab-application 




­ Rapamycin­ is­ an­ inhibitor­ of­ mammalian­ target­ of­
rapamycin­ (mTOR),­ a­ kinase­ member­ of­ signaling­
pathway­that­promotes­tumor­growth.­nab-rapamycin 
(ABI-009)­ currently­ being­ studied­ in­ a­ phase­ I­ trial­
(NCT00635284)36 in various non-hematological malig-
nancies  is  purported  to  overcome  the  poor  aqueous 
solubility and poor chemical stability,­which­had­lim-
ited rapamycin’s development as an anticancer agent. 
17-AAG­(17-­N-allylamino-17-demethoxygeldanamycin; 







Contemporary  cancer  therapeutics,  including  treat-
ment of breast cancer, is centered on the concept of vishnu and Roy
64  Breast Cancer: Basic and Clinical Research 2011:5
  personalized medicine. The emphasis is to tailor ther-
apy­to­each­patient­based­on­specific­tumor­phenotype­
and genomic analysis. Treatment decisions are based 
not only on predictive and prognostic factors, but also 
on­safety­profile,­impact­on­quality­of­life­and­patient­
preference. In the past decade, several studies have 




of solvents used in conventional solvent-based   taxanes. 
Clinical­ data­ show­ that­ nab-paclitaxel  has  a  better 
safety­and­side­effect­profile­with­an­improved­efficacy­
compared to solvent-based taxanes. Higher doses can 
be­administered­over­a­shorter­infusion­time­without­
the need for special infusion sets or   premedications. 
The­phase­II­and­Phase­III­studies­showed­significant­
improvement in tumor response rate and progression 





underway­evaluating­the­role­of­nab-paclitaxel as a sin-
gle­agent­or­in­combination­with­cytotoxic­and/or­bio-
logic agents in breast cancer and other solid tumors.
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